The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma.

OBJECTIVE The prognosis of high-grade glioma (HGG) is poor with a median survival of about 1 year for glioblastoma. In 2007, NICE published a technology appraisal (TA121) recommending the use of carmustine wafers (Gliadel) and systemic therapy with temozolomide for selected patients with HGG. Outcomes for HGG surgery in the United Kingdom with these… CONTINUE READING